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Abstract: The variable lymphocyte receptors (VLRs) consist of leucine rich repeats (LRRs) and
comprise the humoral antibodies produced by lampreys and hagfishes. The diversity of the molecules
is generated by stepwise genomic rearrangements of LRR cassettes dispersed throughout the VLRB
locus. Previously, target-specific monovalent VLRB antibodies were isolated from sea lamprey larvae
after immunization with model antigens. Further, the cloned VLR cDNAs from activated lamprey
leukocytes were transfected into human cell lines or yeast to select best binders. Here, we expand
on the overall utility of the VLRB technology by introducing it into a filamentous phage display
system. We first tested the efficacy of isolating phage into which known VLRB molecules were
cloned after a series of dilutions. These experiments showed that targeted VLRB clones could easily
be recovered even after extensive dilutions (1 to 109). We further utilized the system to isolate
target-specific “lampribodies” from phage display libraries from immunized animals and observed
an amplification of binders with relative high affinities by competitive binding. The lampribodies can
be individually purified and ostensibly utilized for applications for which conventional monoclonal
antibodies are employed.
Keywords: variable lymphocyte receptors; phage display system; library screening; lampribody
1. Introduction
Agnathans diverged from a common vertebrate lineage in the Cambrian period some 500 million
years ago [1], with lampreys and hagfish being the only surviving representatives of this group.
A unique adaptive immune response mediated by single solenoid-shaped molecules synthesized from
highly polymorphic leucine rich repeats (LRR) has been described in lamprey [2] and hagfish [3].
These molecules are expressed in cells resembling B-lymphocytes and are called variable lymphocyte
receptor B (VLRBs). They are assembled on an incomplete genomic template (VLRB locus) by
stepwise recruitment of the LRR cassettes spread across the large locus [2] to form a mature VLRB
(mVLRB), most likely by a gene conversion-like (copy choice) mechanism [4] using very short sequence
homology as described for transposon excision in Escherichia coli [5]. The system has the theoretical
potential of generating a repertoire >1014 different antigen receptors, which is comparable to what
is seen in the immunoglobulin (Ig)-based adaptive immune system in the jawed vertebrates [3,6].
VLRB monoclonal antibodies, hitherto referred to as “lampribodies”, have been produced using soluble
protein, particulate antigens, and whole cells as immunogens, e.g., BclA protein of Bacillus anthracis
exosporium [7], H-trisaccharide of human O-type erythrocyte [8], hen egg lysozyme [9], avian influenza
virus hemagglutinin [10,11], CD38 plasma cells [11], plant pathogen protein HopM1 [12], and murine
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brain extracellular matrix (ECM) [13]. It is of interest to note that the VLRB system has shown
the capability of producing high affinity antibodies against glycotopes, much more so than the
immunoglobulin-based system [14]. VLRBs have also made their way into therapeutic and diagnostic
applications, including monitoring of chronic lymphocytic leukemia [15], blocking the IL-6/STAT3
signaling pathway in non-small cell lung cancer cells [16], delivery of protein–drug conjugates
for tumor regression [17], visualizing protein–protein interaction in live cells [18], suppression of
neovascularization in age-related macular degeneration by blocking the VEGF signaling pathway [19],
neutralizing anaphylatoxin C5a to combat inflammatory disease [20], and applications in gene therapy
with chimeric antigen receptors targeting leukemic B cells and effector T cells [21].
Isolation of the antigen specific VLRB has been accomplished in various ways. These include
cloning the PCR-amplified cDNA from leucocytes into an expression vector and transfecting and
screening human cell lines [2,15]. VLRB amplicons have also been expressed on the surface of yeast to
develop a yeast surface display (YSD) platform for isolating target specific VLRB molecules and for
in vitro affinity maturation [9]. Insect cells have been used with the baculoviral expression system in
order to secrete VLRB protein [22], and HEK-293T human cells have also been used for this purpose [15].
In these methods, random clones from the respective libraries were individually tested for their affinity
to the specific antigen and the best binding clones were isolated for further analysis. Since the first
reporting of the phage display system in 1987 [23], it has been used for many proteins including
genetically engineered VLRB molecules for screening and selection of binders with relative high
affinity [24]. However, the use of the system for generating libraries from immunized lampreys and
for clone selection has never been reported.
In this study, our first objective was to evaluate the robustness of the phage display system in
VLRB expression and target specific binding, and the second objective was to develop a VLRB screening
method based on phage display. First, we used a semi-quantitative means (subtraction experiment)
in order to examine its sensitivity by isolating known VLRB molecules embedded within very large
libraries. Secondly, the system was challenged (by competitive binding) to select target specific VLRB
from libraries of immunized animals. Our results collectively demonstrate that the phage display
system is suitable for isolating the highest affinity VLRB molecules from libraries, resulting in clonal
expansion of such molecules. The lampribodies so generated should be usable for many applications
in biology and are highly amenable to an open source model of communal distribution.
2. Results
2.1. Testing the Driver VLRB Molecules in M13 Phage Display System
In order to examine target specific binding of the VLRB molecules expressed in a phage display
system, we used the previously published variable regions of anti-lysozyme VLRB molecules,
VLRB.HEL.1, VLRB.HEL21, and VLRB.HEL2D [9]. Full-length anti-lysozyme VLRB molecules
were synthesized from the respective variable regions by adding the conserved 5′ and 3′ regions of
VLRB. The synthesized molecules were amplified and subsequently cloned into the phagemid vector,
pADL-10b, yielding a fusion protein with the pIII coat protein of the phage as described schematically
in Figure 1A,D using primers in Table S1.
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Figure 1. Cloning of anti-lysozyme VLRB, VLRB.HEL in a phagemid vector and construction strategy
of VLRB library. (A) Three full-length anti-HEL VLRBs, diversity region mRNA, partial coding
sequences were extracted from GenBank and conserved regions were added to the 5′ and 3′ ends
to construct full-length molecules. VLRB.HELs were then synthesized and amplified by PD-VLRB.F
(forward) and PD-VLRB.R (reverse) primers for directional cloning into the phagemid vector. (B)
Unimmunized (also for immunized) lamprey larvae were euthanized, and organs harvested. Total
RNA and then polyA RNA was isolated from the typhlosole of unimmunized (buffy coat of immunized
animals). PolyA RNA was converted to cDNA which was used as a template for preparation of
VLRB amplicon library by PCR with PD-VLRB.F and PD-VLRB.R primers. (C) Agarose gel (1.5%)
electrophoresis of VLRB amplicons from typhlosole from unimmunized animals mentioned above.
A ladder pattern ranging from 0.8 to 1.2 kb was seen. (D) The VLRB amplicon libraries from the
typhlosole and each of the VLRB.HELs were digested with BglI and directionally cloned in phagemid
vectors, pADL10b or pADL23c. The sequence of the insert was determined using a forward primer
(CAPBSF1) and a reverse primer (GPIIICTR2) located upstream and downstream of the cloning site
respectively. Approximately 70% of the single colonies had inserts ranging from 0.5 to more than 1.0 kb,
the remaining colonies either possessing small inserts or no inserts. The number of recombinants in the
library was approximately 7 × 105 (7.0 × 106 cfu/µg of insert DNA). A small number of the phagemid
clones with estimated inserts ≥0.7 kb was sequenced to see if the library had full-length VLRB, and to
assess their sequence diversity. Sequences for 27 clones were obtained, all of which were full length
and encompassed unique VLRBs. Their putative protein sequences showed extensive homology with
the reported VLRBs in the non-redundant protein sequences database (data not shown).
M13 phages were prepared using Hyperphage (M13K07 ∆pIII) [25] in TG1 E. coli cells. To test the
relative binding affinity, approximately 1.0 × 109 plaque forming units (PFU) of each phage were used
in ELISA detection of two-fold serial dilutions on streptavidin microtiter plates coated with biotinylated
lysozyme. The results (Figure 2A) clearly showed binding of phages expressing VLRB-pIII recombinant
protein to hen egg lysozyme. The binding affinity of VLRB.HEL21 phage was higher than that of
VLRB.HEL1 and VLRB.HEL2D phages; approximately 0.97 million PFU of recombinant phages or more
showed appreciable optical density (OD) readings (>0.1 OD) for each of these phages. No appreciable
binding of any of the phages was seen in wells without bait and the OD values were comparable to those
obtained with blocking buffer with and without bait. It demonstrated that the binding affinity of the
phages to plastic was equally negligible as that of the blocking buffer. Based on this result, these VLRB
clones were considered suitable for use as drivers in the assessment of the screening method. We also
examined the expression of VLRB-pIII fusion protein of VLRB.HEL21 and VLRB.HEL2D phages by
Western blotting. Crude lysates prepared from phages by heating the suspensions with reducing buffer
were used for SDS-PAGE. VLRB-pIII was detected by mouse monoclonal anti-VLRB antibody, 4C4 [3].
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Crude phage lysate from VLRB.HEL21 showed a 77 kD band matching the size of the VLRB-pIII fusion
protein (arrowhead in Figure 2B). Owing to the crude nature of the phage lysates, additional bands are
seen which are possibly attributed to spurious interactions between VLRB (and/or primary antibody)
with other proteins as well as degradation of fusion proteins. However, VLRB.HEL2D phage showed
a single band of expected size. To differentiate the VLRB-pIII fusion protein, bacterially expressed
VLRB.HEL21 protein was included in this experiment. VLRB.HEL21 was cloned in pET28+ vector and
His-tagged VLRB.HEL21 recombinant protein was isolated and differing amounts were run on the
gel. Antibody 4C4 detected a 32 kD band corresponding to the size of the recombinant VLRB.HEL21.
Therefore, the experiment clearly verifies the VLRB-pIII fusion protein in the phages and the presence
of VLRB monomeric form expressed from E. coli.
Figure 2. VLRB.HEL recombinant M13 phage preparation and ELISA test for its binding to lysozyme.
(A) Each well of an ELISA plate was coated with 50 ng of biotinylated hen egg lysozyme to which
100 µL of blocking buffer was added. To prepare two-fold serial dilutions of the phage, 100 µL of phage
(2 × 109 PFU) was transferred to the first well, mixed, and then 100 µL solution from the first well
was transferred to the second well and mixed. The series of two-fold serial dilutions was continued
for the rest of wells in the same row, with and without the bait. WB: with bait; NB: no bait in the
wells in a particular row. ELISA was carried out using standard procedures. Optical density at 450
nm was plotted against the number of phage PFUs per respective well. Blocking buffer alone was
used to assess background binding of the phages as well as for control experiments employing the
primary antibody only (no phages). The arrowhead on the right underneath the X-axis marks the phage
concentration at which the binding became appreciable; that on the left marks the phage concentration
at which the binding reached a plateau for all the phages. Numbers in X-axis denotes serial half dilution
of the phage solutions from 1 × 109 to 4.88 × 105 PFU. (B) Phages prepared from VLRB.HEL21 and
VLRB.HEL2D were examined for the expression of VLRB-pIII fusion protein. Approximately 4 × 109
PFUs were heated to 95 ◦C for 5 min in reducing buffer and run in an SDS-PAGE gel. His-tagged
VLRB.HEL21 protein was isolated by cloning the full-length fragment into pET28+ vector and expressed
in E. coli BL21. Serial concentration of His-tagged eluate of VLRB.HEL21 was used to demonstrate the
presence of the protein. Lane assignments: 1, ProSieve Color Protein Marker in kD; 2, VLRB.HEL21
phage; 3, VLRB.HEL2D phage; 4–6, His-tagged VLRB.HEL21 protein 1, 2, and 4 µg respectively; 7.
Zebrafish protein, 5 µg (used as a negative control. Arrowheads indicate the position of the bands
with estimated molecular weights of VLRB-pIII fusion protein and bacterially expressed His-tagged
VLRB.HEL21 protein in the blot.
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2.2. Construction and Characterization of a Competitor Phage Display Library
The efficacy of the phage display screening for isolation of target specific lampribodies was
tested by a subtraction experiment using a phage library of VLRB transcripts from unimmunized
(naïve) sea lampreys spiked with a VLRB.HEL phage constructed above. As such, a VLRB library was
constructed from the typhlosole (hematolymphoid organ) of two unimmunized lamprey larvae and
characterized for its affinity for lysozyme as shown schematically in Figure 1A,B,D, representative PCR
of the library showed diversity in size of the products (Figure 1C). Sequencing showed that the library
consisted of full-length VLRB molecules with variable numbers of LRR cassettes and polymorphisms
within them [26], and represented sufficient and non-redundant sequence diversity (detail analysis
in Table S2). The competitor phage library to be used for developing the screening method spiking
with an anti-lysozyme VLRB driver phage will need to be devoid of any anti-lysozyme VLRB phage.
Lysozyme binding of the library was examined by biopanning (described in Figure S1). After two
rounds of biopanning, duplicate screening experiments were performed to isolate high affinity VLRB
binders (Table S3 and Figure S2). No true binder was found; a few binders showing higher affinity in
screening were further verified and were found to be false positives (Table S4 and Figure S3). This led
to the conclusion that the library was devoid of any strong anti-lysozyme VLRB and could therefore be
used for spiking with anti-lysozyme VLRB molecules for a subtraction experiment.
2.3. Subtraction Experiment for Recovery of the Driver Phage by Panning
In the subtraction experiment (described in Figure S4), the naïve phage library was spiked with the
anti-lysozyme phage harboring VLRB.HEL21 which showed highest surface plasmon resonance (SPR)
value [9]. In duplicate experiments, 1 PFU of VLRB.HEL21 phage was mixed with 109 PFU of the library
and the mixture was applied to lysozyme for biopanning. After two rounds of biopanning, the spiking
phage, VLRB.HEL21, was recovered in both of the duplicate screening experiments (Table S5 and
Figure S5) at percentages of 8.33 and 39.58 (Table S6). This result demonstrates that the system is
sensitive enough to recover a target specific VLRB from a pool of a billion such molecules at a significant
quantity even when present in a single copy.
2.4. Immunization of Lamprey Larvae with Lysozyme and Isolation of Anti-Lysozyme VLRB Clones
Experiments were carried out to determine whether the VLRB phage display system was capable
of isolating lampribodies from sea lampreys when challenged with a known immunogen, lysozyme.
Three lamprey larvae were injected with KLH-conjugated lysozyme (see Materials and Methods). As a
first step, the plasma from the immunized animals was examined for antigen binding by ELISA with
biotinylated lysozyme. A ten-fold serial dilution of the plasma, 10−1 through 10−12, from each animal
was used for ELISA with and without bait, and antibody 4C4 was used to detect lysozyme-bound
VLRB molecules. The ELISA results demonstrated notable binding with the antigen at 10−4 dilution of
the plasma from all three animals (Figure 3). These results, based on plasma reactivity, indicated that
the immunization course yielded a good response.
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Figure 3. ELISA results of the plasma from three lysozyme-immunized sea lampreys showing reactivity
against biotinylated bait and no bait. Serial ten-fold dilutions of the plasma were added to wells with
and without the bait. A1, A2, and A3 are the individual animals, WB: with bait, NB: with no bait in
the wells. Solid triangle underneath the X-axis marks the lowest limit of appreciable OD. Numbers in
X-axis denotes serial half dilution of the phage solutions from 10−1 to 10−12. WB denotes with bait,
and NB no bait in the wells in that row.
In order to construct phage display libraries, polyA RNA isolated from the white blood cells of
one of the immunized animals (animal 1) was used for cDNA synthesis. The VLRB specific primers,
PD-VLRB.F and PD-VLRB.R (Table S1) were used for PCR amplification of cDNA from animal 1.
The amplicons were cloned into the phagemid vector pADL-10b to generate a library of full-length VLRB
molecules, which were then propagated as phagemids. Efficiency of ligation was examined by PCR of
24 independent colonies with the same set of forward and reverse primers used for unimmunized
animals (Table S1). All the clones contained inserts of variable sizes, and the number of recombinants in
the library was approximately 9.0 × 105/µg insert DNA (~90,000 primary recombinants). Phages were
generated from these phagemids and subsequently used for panning against biotinylated lysozyme
on ELISA plates. Selective phage binding to the biotinylated lysozyme was monitored by calculating
the percentage of recovery of the trapped phages using standard procedure for both phages bound
to the bait and phages bound to the empty plate without bait (negative control). Nearly sevenfold
more colonies were obtained from the bait-bound recovered phages suggesting the presence of target
binding phages after the first panning. Bait-bound phages were recovered, amplified, and used for a
second round of panning with and without bait. After recovering the phages, a small aliquot of infected
E. coli was plated to obtain independent clones. Colonies were obtained only from the bait-bound
recovered phages and no colonies were obtained from the negative control, suggesting significant
selection of positive binders. Phagemids were isolated from 24 independent colonies and insert sizes
were examined by PCR; all were positive for inserts of equal size (data not shown). Phages were
prepared in batch from 12 of these colonies and screened for bait binding by ELISA and all were found
to be positive. Inserts in these ELISA positive phagemids were sequenced. Among the 7 full-length
VLRB sequences, 6 were identical (called Clone A) and another (called Clone B) differed by a single
base at the 619th position (transition A to G) resulting in one residue change from threonine to alanine
at the 207th position in the stalk region. Resequencing was not done for the remaining 5 phages as
clonal expansion had already been observed in the 6 Clone A sequences. Fresh phages were prepared
from one of the 6 identical clones for ELISA with lysozyme. The result (Figure 4) showed specific
binding to lysozyme.
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Figure 4. Confirmation of lysozyme binding by purified clone from the screening experiment.
Lysozyme binding of one VLRB clone isolated from the immunized animal (A1), 10bLysA1P2_1 was
examined by making phage from log phase culture by ELISA. Serial half dilutions beginning with
109 PFU were added to wells in a microtiter plate coated with biotinylated lysozyme. Wells without
biotinylated lysozyme were used as negative controls. WB, with bait; NB, no bait in the wells.
Numbers in X-axis denotes serial half dilution of the phage solutions from 1 × 109 to 4.88 × 105 PFU.
Alignment of the deduced protein sequence showed that the VLRB in the Clone A phage (Figure S6)
was different from the three previously published VLRB.HEL clones and showed only 86–91% identity
between them. Clone A showed no difference at the threonine residue from the other VLRB.HEL
clones. Therefore, the single base transition seen in Clone B could be due to a de novo mutation from
clone A or a naturally occurring variant and was selected because it did not compromise the binding
affinity. Regardless, the fact that we saw clonal expansion after only two rounds of panning indicates
that phage display is a viable method of screening. The fact that our isolated VLRB lampribodies
showed only 86–91% identity to the previously isolated clones may be due, in part, to the fact that
rearrangements are generated de novo in the lampreys and that the animals we use for our experiments
are from an outbred source.
2.5. Isolation of VLRB Against Human IgM Protein
Human IgM protein crosslinked to paraformaldehyde-fixed Jurkat T cells was used for
immunization of lamprey larvae (see Materials and Methods). The cDNA isolated from the leukocytes
was used to amplify VLRB sequences with primers to the 5′ and 3′ untranslated regions (Table S1).
Approximately 100 ng of the PCR product thus amplified was re-amplified with PD-VLRB.F and
PD-VLRB.R primers for 10 cycles (to avoid accumulation of nonspecifically primed and PCR mutated
products). The amplicons were cloned into the pADL10b phagemid vector and a phage library was
prepared. The number of recombinants in the library was approximately 1.6 × 109/µL of insert DNA
(1.6 × 108 primary recombinants). The library was used for panning against human IgM, and phages
recovered after the third round of panning were used to infect E. coli. Single colonies were obtained
by plating an aliquot of the infected cells. PCR amplification of the inserts of 48 randomly isolated
phagemids showed uniformity in the size of the inserts. Of these, 24 phages were screened for IgM
binding by ELISA; 23 showed positive binding (data not shown). Of the ELISA positive phages, 10
were sequenced to determine if they had full-length VLRB molecules. The result showed that one was
810 bp and the remaining 9 clones were 807 bp (Table S7); all were full-length VLRB. In the 9 VLRB
phages of equal length (807 bp), there were two groups of identical clones, 2 in one group (called Clone
A), 4 in another (called Clone B); the remaining 3 were non-clonal. Alignment of the DNA and the
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predicted protein sequences of the representatives of Clone A (10bIgM3P_4), Clone B (10bIgM3P_6),
and the 4 unique clones (10bIgM3P_1, 10bIgM3P_3, 10bIgM3P_5, 10bIgM3P_2) revealed that the
polymorphism found in all these clones were primarily confined to two locations, one within the
connecting peptide (CP) region and the other in the C-terminal immediately upstream of reverse primer
sequence (PD-VLRB.R) used for initial amplification of VLRB library. To determine the occurrence of
the polymorphic bases, the sequences were compared against the non-redundant database in NCBI and
mismatched bases were termed polymorphic. In case of Clone A (10bIgM3P_4) and another unique
clone (10bIgM3P_3), the CP sequence was CATCTATCTGTT and in case of Clone B and two other
clones (10bIgM3P_1 and 10bIgM3P_5), it was GATCTGGCTGTA (the bolded bases are polymorphic
in Figure S7A). This short CP sequence in Clone A was found in the non-redundant database, but that
of Clone B could not be found. At the 3′ of the stalk region, the polymorphic sequence in Clone A
was GCTA and in Clones B and 10bIgM3P_3, it was TCTG. In this case, the sequences in Clone A
and Clone 10bIgM3P_1 (GCTA and CCTG) were not found in the non-redundant database, but the
other sequence was found. In another clone (10bIgM3P_5), the 3′ region showed a T to C transition,
however, it was found in the non-redundant database. Clone 10bIgM3P_2 (810 bp) was the only one
showing polymorphism in the LRRCT region and it was not found in the non-redundant database.
The polymorphisms in the CP region and 3′ of the stalk region of the affinity selected molecules may
or may not represent true variants as the cloning of the library involved two rounds of amplification
by PCR. Figure S7B shows the alignment of the deduced proteins sequence of the phages in S7A.
Phages 10bIgM3P_1 (non-clonal), 10bIgM3P_2 (non-clonal), 10bIgM3P_4 (Clone A) and 10bIgM3P_6
(Clone B) were grown up to exponential phase and phages were prepared for ELISA with IgM, and the
result showed comparable binding (Figure 5).
Figure 5. ELISA result of the four non-redundant VLRB clones against human IgM isolated by phage
display screening. Each well of an ELISA plate was coated with 75 ng of biotinylated human IgM.
Serial two-fold dilution of 1010 PFU of each of the phages was used. Each sample was used with and
without bait. WB: with bait; NB: no bait in the wells. Numbers in X-axis denotes serial half-dilution of
the phage solutions from 1 × 109 to 4.88 × 105 PFU.
Clone A (VLRB.IgM3P_4) was introduced in phagemid vector pADL23c to isolate recombinant
lampribody; this vector contains 6×His tag at the C-terminal for isolation of the recombinant protein and
an amber mutation between VLRB and pIII to produce recombinant protein only instead of pIII fusion
protein. Coomassie brilliant blue (CBB) stain of the SDS-PAGE shows that the recombinant protein
expressed in E. coli was heavily contaminated with other proteins; a specific band of the estimated
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molecular weight of 32 kD could not be discerned after purification with Ni-NTA beads (Figure 6A).
Similar results were obtained after cloning VLRB.IgM3P_4 into pET28+ vector and expressing in
various host E. coli strains (data not shown). Further optimization of the culture and purification
conditions for VLRB is underway. Western blotting with mouse monoclonal anti-VLRB antibody
4C4 showed the expected band in the purified fraction (Figure 6B). A smaller band of approximately
22 kD was found in the lysate after induction with IPTG (lane 1, Figure 6B), which is most likely
a nonspecific protein binding to 4C4 antibody or a bacterially cleaved VLRB C-terminal fragment.
This result suggested that the His-tag extract contained less than 10% of the actual recombinant protein.
When expressed in insect cells Sf9, the protein was much less contaminated (data not shown).
Figure 6. SDS-PAGE and Western blot analysis of the bacterially expressed anti-IgM VLRB lampribody.
(A) Approximately 2 mg of pooled His-tag eluate of VLRB.IgM3P_4 was run and stained with
Coomassie brilliant blue (CBB). Lanes: M, ProSieve Color Protein Marker in kD; 1, 5 mg of cell lysate
after induction with IPTG; 2, 2 mg of pooled VLRB.IgM3P_4 protein; 3, 5 mg of Zebrafish muscle
protein for comparison; 4, 2 mg of His-tagged VLRB.HEL21 protein. (B) An identical gel was run for
Western blotting. Zebrafish protein and and VLRB.HEL21 protein were used as negative and positive
controls for the primary antibody, 4C4.
Histological sections of human tonsil (lymphoid) tissue were subjected to IHC using the extract
described above, which specifically stained a subset of cells, presumably IgM (Figure 7). The lampribody
VLRB.IgM3P_4 has a cMyc tag in the C-terminal from pADL23c phagemid. Therefore, anti-cMyc
antibody was used to detect VLRB.IgM3P_4. Positive staining of the IgM cells by VLRB.IgM3P_4
was also detected using 4C4 (data not shown). For the positive control, mouse IgG anti-human IgM
antibody was used.
Figure 7. Immunohistochemistry using anti-IgM lampribody. Histological sections of human tonsil
(lymphoid) tissue were stained with (A) lampribody, VLRB.IgM3P_4 or (B) mouse IgG anti-human IgM
antibody. The detection of the VLRB was done using anti-cMyc antibody. The final detection was done
with HRP-conjugated rabbit anti-mouse IgG secondary and using diaminobenzidine (DAB) substrate.
Cells reacting positively with the lampribody (A) and the IgG reagent (B) were stained dark brown.
(C) Negative control was stained similarly except without any primary antibody.
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3. Discussion
Generation and isolation of antigen-specific lampribodies using phage display technology has
been clearly demonstrated in the above experiments using lysozyme and human IgM as immunogens.
The screening in phage display libraries relies on competitive binding and selection of the monomeric
lampribody fused to the pIII molecule of the recombinant phage in each panning step. This allows for
isolation of high affinity binders and their clonal expansion. By contrast, the screening method for
isolating the binders in eukaryotic cells and yeast surface display does not allow competitive binding.
Amplification of the relative high affinity binders in the panning rounds was observed in the case of
both anti-lysozyme and anti-human IgM phage display screening. This was most likely due to the
stringent screening conditions employed to eliminate selection of false positive clones.
By varying the stringency, the system should allow isolation of polyclonal lampribodies against
an immunogen. It would also be interesting to map the epitopes in case of polyclonal responses. In a
preliminary experiment, phages containing VLRB.HEL1, VLRB.HEL21, and VLRB.HEL2D molecules
were mixed together with a näive VLRB phage display library at a ratio of 1 to one million. After the
first round of panning under less stringent conditions, all three VLRB.HEL phages were recovered,
emulating a polyclonal response. In the extreme dilution experiment described above, we used the
same strategy to make serial dilutions of one of these (VLRB.HEL21) at a ratio of 1 to one billion and we
were still able to faithfully recover the clone after only 3 rounds of selection. These results conclusively
show that the VLRB sequences identified by another method (yeast surface display) can readily be
selected when cloned in a phage display system.
Here, we have shown that the phage display system can be adopted to the variable lymphocyte
receptors of the sea lamprey. The advantage of working with such a prokaryotic system is the ease
at which the antibody repertoire can be cloned and screened. The reagents used for constructing
and screening the library are off-the-shelf components and building these libraries is relatively easy
and can be accomplished by most molecular genetics laboratories. The lampribodies so produced
should be useful for most applications that conventional antibodies are used for and can easily be
multimerized for use in certain cell biology applications. The lampribodies recognize both peptide
epitopes [7] and glycotopes [13] and the phage display technology should prove useful as a screening
tool when immunizing with more complex antigens, including whole cells. The key component in the
generation of lampribodies is the immunization of the lampreys and capturing of its immune response
as PCR amplicons. This technology should be portable to many laboratories that wish to generate a
wide swath of reagents and is amenable to reagent sharing via an open source model.
4. Materials and Methods
4.1. Animals
Wild type sea lamprey larvae of 12–15 cm length were obtained from Acme Lamprey Company,
Maine. Animals were maintained in partially sand filled aquariums at 16–18 ◦C and were fed on
brewer’s yeast. All experiments were performed upon approval by the Institutional Animal Care
and Use Committee at Western Fisheries Research Center, Seattle, Washington. For immunization by
intraperitoneal injection, lamprey larvae were sedated in 0.1 g/L of MS222 (tricaine methanesulfonate,
Sigma, St. Louis, MO, USA) buffered with sodium bicarbonate. The animals were euthanized by
immersion into 1 g/L of MS222 buffered with sodium bicarbonate for collection of blood and organs.
4.2. Immunizations
Sea lamprey larvae were immunized as described in [6] with minor modification. Lysozyme from
chicken egg white (Sigma) was conjugated with keyhole limpet hemocyanin (KLH) using Mariculture
KLH and EDC Conjugation Kit (Fischer Scientific, Lenexa, KS, USA) according to the manufacturer’s
instructions. The conjugation reaction mixture was dialyzed against phosphate-buffered saline (PBS)
overnight at 4 ◦C. Concentration of the conjugated lysozyme was measured by Pierce BCA Protein
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Assay Kit (Thermo Scientific, Fresno, CA, USA), divided into aliquots, and stored at −80 ◦C. For each
immunization, 70 µg of the conjugated lysozyme in 30 µL volume mixed with equal volume of
Imject Alum (Fischer Scientific) was used according to manufacturer’s instructions. Three doses of
immunogen were injected intraperitoneally every 2 weeks at 4, 6, and 8 weeks. Each animal was
euthanized two weeks after the final injection. When signs of life were undetectable, 100 µL of PBS with
30 mM EDTA were injected into the peritoneal cavity to generate intracoelomic pressure. The tail was
immediately severed 1 mm proximal to the cloacal opening. Blood was collected in a tube containing
0.5 mL of PBS with 30 mM EDTA, mixed well by inverting and immediately centrifuged at 106× g
for 2 min. Plasma was separated and stored at −80 ◦C and the cells were resuspended in 0.5 mL of
PBS with 30 mM EDTA and kept on ice until the isolation of buffy coat. The animal was dissected by
ventral midline incision, and the kidneys, intestine and typhlosole were harvested, snap frozen, and
stored at −80 ◦C. To isolate the buffy, the cell suspension was gently pipetted into a 2 mL microfuge
tube containing 1 mL of 55% Percoll (GE Healthcare, San Ramon, CA, USA) and centrifuged at 4 ◦C at
400× g for 5 min in a swing bucket rotor with minimal setting of speed ramp and brake. The buffy coat
was isolated (0.2 to 0.3 mL) and mixed with 0.75 mL TRIzol reagent (Invitrogen, Waltham, MA, USA)
and stored at −80 ◦C until further processing. Blood and organs from unimmunized animals were
isolated using the same procedure.
All experiments of immunization of sea lamprey larvae (obtained from Lamprey Services,
Ludington, MI) with human IgM protein were done at Emory University with the approval of the
Emory University Institutional Animal Care and Use Committee (IACUC). For immunization, purified
human IgM from plasma (EMD Millipore, Temecula, CA, USA) was coupled to fixed Jurkat T cells
as an adjuvant. 108 Jurkat T cells were fixed overnight in 4% paraformaldehyde, then washed in
20 mM MES, pH 5.5, and activated with EDC/NHS (1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide
hydrochloride/N-hydroxysuccinimide) for amine conjugation for 20 min at room temperature. The cells
were briefly washed in PBS, then 0.5 mg of human IgM in 1 mL of PBS was added to the pelleted
EDC/NHS-activated cells for 3 h at room temperature on a rotating mixer. At the end of the conjugation
reaction, the cells were centrifuged at 400× g and the supernatant was removed, then the cells were
washed in PBS with 10 mM Tris, pH 7.5. The IgM conjugated Jurkat cells were stored at 4 ◦C until
needed for immunization. Lamprey larvae were sedated with 0.1 g/L tricaine methanesulfonate
(Tricaine-S; Western Chemical, Inc., Riverside, CA, USA), before injection with 107 IgM conjugated
Jurkat cells resuspended in 30 µL of PBS, such that each lamprey received approximate 50 µg of
recombinant IgM using the same immunization schedule as that for lysozyme.
4.3. Naive VLRB Phage Display Library Construction
Two unimmunized animals were used for this purpose. From each, total RNA was extracted from
20 mg typhlosole using TRIzol reagent (Invitrogen, Waltham, MA, USA). From the total RNA, polyA
RNA was isolated using NucleoTrap mRNA Mini Kit (Clontech, Mountain View, CA, USA). An aliquot
of the polyA RNA was used for cDNA synthesis using SuperScript III (Invitrogen). Entire VLRB
molecule including the hydrophobic tail was amplified from the typhlosole cDNA PD-VLRB.F and
PD-VLRB.R (Table S1). The forward primer contains a 6 basepair insert, atggcg, to obtain complete PelB
leader encoding sequence. Both forward and reverse primers contain SfiI/BglI overhang for directional
cloning of VLRB inserts in pADL phagemid (Antibody Design Laboratories, San Diego, CA, USA).
Agarose gel electrophoresis of the PCR products showed a size range of 0.8 to 1.2 kb. The PCR products
were digested by BglI restriction enzyme and 50 ng of the digested product was ligated to 25 ng BglI
digested and dephosphorylated phagemid vector (pADL) overnight at 16 ◦C (Figure 1C). The reaction
mixture was extracted twice with phenol: CIAA, precipitated in ethanol and resuspended in 10 µL of
water. From this, 2 µL were used to transform electrocompetent TG1 E. coli. The cells were recovered in
1 mL of 2× YT supplemented with glucose and thiamine-HCl to a final concentration of 2% and 1 mM,
respectively, and grown for 1 h at 37 ◦C with shaking at 250 rpm. After the incubation, 10 µL of the
culture was taken out and plated for determination of independent clones. The rest of the cells were
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grown for 6 h in 2× YT containing 2% glucose and 1 mM thiamine-HCl and 100 µg/mL carbenicillin to
prepare the primary library. Half of this library was used to prepare phage and the remaining half was
stored at −80 ◦C adding 20% glycerol. Similarly, phagemid library was constructed from the buffy
coat of animals immunized by lysozyme. For a VLRB library against human IgM, RNA was isolated
from the buffy coat and reverse transcribed into cDNA with oligo-dT priming. VLRB transcripts were
amplified from the cDNA by PCR using primers specific for the 5′ and 3′ untranslated region (Table S1).
4.4. Subcloning of Anti-Hen Egg Lysozyme (HEL) VLRB Molecules for Phage Display
Diversity region mRNA of VLRB.HEL.21, VLRB.HEL.1, and VLRB.HEL.2D (GenBank accessions
FJ794807, FJ794806, and FJ794805 respectively) were extracted (Figure 1A). Full-length VLRB sequences
were constructed in silico by adding conserved 5′ and 3′ sequences to the diversity regions gene
fragments and the constructs were synthesized (Life Technologies, South San Francisco, CA, USA) with
BglI restriction enzyme sites for directional cloning into phagemid vectors, pADL10b or pADL23c.
4.5. Phage Preparation from the VLRB Phage Display Libraries and the VLRB HEL Phage Display Clones
To 0.5 mL of the primary library, 9.4 mL of 2× YT containing 2% glucose and, 1 mM thiamine-HCl,
100 µg/mL carbenicillin and 100 µL of 1010 PFU of Hyperphage (M13K07∆pIII, Progen Biotechnik
GmbH, Germany) were added and the culture was grown for 1 h at 37 ◦C with shaking at 250 rpm.
The culture was centrifuged at 2000× g for 10 min at 4 ◦C and supernatant was discarded as much as
possible to get rid of the traces of glucose. The cells were resuspended in 10 mL of 2× YT medium and
carbenicillin, kanamycin was added to a final concentration of 100 µg/mL, and IPTG to 250 µM and
incubated at 30 ◦C for 20 h. The culture was centrifuged at 10,000× g for 20 min at 4 ◦C, the supernatant
containing recombinant phages was collected. To precipitate recombinant phages, first equal volume
(10 mL) of blocking buffer (PBS with 0.05% Tween 20 and 1% BSA) was added to the recombinant phages
and incubated for 10 min on ice; then 20% polyethylene glycol was added to a final concentration
of 3.33% and incubated on ice for 1 h. It was then centrifuged at 10,000× g for 20 min at 4 ◦C.
The supernatant was discarded, and the pellet was resuspended in 0.4 mL of ice-cold PBS. The phage
solution was transferred in a sterile microfuge tube and centrifuged at 14,000 rpm for 10 min at 4 ◦C.
The supernatant was saved in a sterile microfuge tube and stored at 4 ◦C. For, VLRB.HEL phagemid
clones, single colony was isolated from each of the TG1 cells transformed with VLRB.HEL phagemid
and grown in broth up to exponential phase and 1 mL of the culture was used to prepare phage as
described above.
4.6. Titering the VLRB Phage Display Libraries and Individual VLRB.HEL Phage
TG1 cells from glycerol stock were spread on 2× YT agar plate with 2% glucose and 1 mM
thiamine-HCl (2× YTGT). Single colony was isolated from overnight plate culture and used to inoculate
10 mL of 2×YT liquid broth with 2% glucose and 1 mM thiamine-HCl and incubated at 37 ◦C with
shaking at 250 rpm. The cells were grown until the optical density (OD) at 600 nm reached 0.4–0.6.
The culture was immediately chilled on ice slurry and kept on ice until use. Ten-fold serial dilutions of
the phage solution of the library was made in 2× YT medium. To 100 µL of 10−6, 10−7, 10−8 dilutions of
the phage solution, 100 µL of pre-chilled exponential-phase TG1 cells were added. After gentle mixing,
incubation was continued at room temperature for 15 min. Each dilution was plated on to 2 plates
and incubated overnight at 37 ◦C. Plates having 30 to 300 colonies were counted and the titer of the
phage solution was determined. Titer of individual VLRB.HEL phage solution was determined in the
same way.
4.7. Biotinylation of the Bait and ELISA Screening
Lysozyme from chicken egg white (Sigma, Burlington, MA, USA) was dissolved in water to a
final concentration of 10 mg/mL, 0.2 mg of the solution was labeled with biotin using EZ-Link Micro
NSH-PEG4—Biotinylation Kit (Thermo Scientific, Fresno, CA, USA) according to manufacturer’s
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instructions. Biotinylation was estimated using Pierce Biotin Quantitation Kit (Thermo Scientific)
and lysozyme concentration after labeling was measured by Pierce BCA Protein Assay Kit (Thermo
Scientific). Pierce Streptavidin High Binding Capacity Coated 96-Well Plates (Thermo Scientific) were
washed three times with wash buffer (1× PBS with 0.05% Tween 20). Biotinylated lysozyme was diluted
to 0.5 ng/µL with 1× PBS and 100 µL were used for coating each well (50 ng per well). The plates were
incubated at 37 ◦C for 1 h or 4 ◦C for a minimum of 4 h on Maxi Rotor (Lab Line) with shaking at 10 rpm.
The same setting of the rotor was used throughout the experiment. The bait solution was removed,
and the wells were washed three times with wash buffer. Blocking buffer (200 µL) was added to each
well, and incubated at 37 ◦C for 1 h or 4 ◦C for a minimum of 4 h. The blocking buffer was removed,
and the wells were washed three times with wash buffer. To each well, 50 µL of phage solution mixed
with equal volume of blocking buffer was added and incubated at 37 ◦C for 1 h or 4 ◦C for a minimum
of 4 h. In the case of plasma from immunized animals, 50 µL of dilute plasma were mixed with equal
volume of blocking buffer and added to the well. The phage solution was removed, and the plate was
washed 5 times with wash buffer. HRP/anti-M13 Monoclonal Conjugate (GE Healthcare) was diluted
1:2500 in blocking buffer and 100 µL was added to each well and incubated at 37 ◦C for 1 h or 4 ◦C for
a minimum of 4 h. The antibody was removed, and the wells were washed 5 times with wash buffer.
Equal volume of peroxidase substrate (TMB) and peroxidase solution (Thermo Scientific) was mixed
and 100 µL were added to each well and incubated at room temperature for 20 min, until a suitable
blue color developed. The reaction was stopped by adding 100 µL of 2M sulfuric acid. The absorbance
of each well was measured at 450 nm using OptiMax Tunable Microplate Reader (Molecular Devices).
In case of plasma from immunized animals, VLRB antibody 4C4 (6) was used as the primary antibody
and it was further detected by peroxidase-conjugated rabbit anti-mouse IgG in 1:500 dilution (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA, USA)
4.8. Panning, Rescue, and Superinfection
Panning was performed as shown schematically in Figure S1. First round of panning:
Biotinylated bait (lysozyme) coated plates were prepared as described above. For panning, 109
phage PFUs were used. The solution was prepared by mixing 50 µL of the phage containing a
maximum of 109 phage PFUs with 50 µL of blocking buffer. At first the total 100 µL phage suspension
was applied to an empty well (without coating with biotinylated lysozyme) and incubated at 37 ◦C
for 30 min. This pretreatment step was done to eliminate non-specific phages. After that the phage
suspension was recovered by pipetting and transferred to a biotinylated lysozyme coated well. The plate
was incubated 37 ◦C for 1 h or 4 ◦C for a minimum of 4 h. The unbound phage suspension was removed,
and the wells were washed 6 times with wash buffer. To each well, 100 µL of 0.2 M glycine-HCl, pH 2.2,
was added and the plate was incubated at room temperature for 15 min to release the bound phages.
In a microfuge tube, 100 µL of 0.2 M Tris-HCl, pH 8.0 were added and kept on ice. After 15 min, the
glycine-HCl solution was pipetted out of the well and added to the microfuge tube containing Tris-HCl
solution to neutralize the solution, the total volume of the phage solution became 200 µL. TG1 cells
were grown to exponential phase from a single colony, as described above. The culture was divided
into 2 mL aliquots in 15 mL culture tubes and 200 µL of released phase solution was added to each.
The tube was incubated at 37 ◦C for 30 min without shaking and another 30 min with shaking at
250 rpm. The culture was centrifuged at 2000× g for 10 min at 4 ◦C and supernatant was discarded
as much as possible to get rid of the traces of glucose. The cells were resuspended in 100 µL of 2×
YTGT broth, representing the enriched phage library. From this, 10−1, 10−2, and 10−3 dilutions were
prepared in 100 µL of 2× YTGT medium and plated in 2× YTGT carbenicillin (100 µg/mL) agar plates
and incubated at 37 ◦C overnight. The colonies were counted, and the percent of phage recovery was
calculated. To prepare phage, 1 mL of 2× YTGT broth was added to 50 µL of cells suspension from
enriched phage library and incubated at 37 ◦C for 1 h. Then, 100 µg/mL carbenicillin and 5 × 109
PFU of Hyperphage were added and the incubation was continued at 37 ◦C for 1 h with shaking at
250 rpm. The culture was centrifuged at 2000× g for 10 min at 4 ◦C and supernatant was discarded as
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much as possible to get rid of the traces of glucose. The cells were resuspended in 10 mL of 2× YT
medium and phage preparation was continued as described above. The rest of the enriched phage
library (approximately 40 µL were stored in 10% glycerol at −80 ◦C. Phage solutions were stored at
4 ◦C. Panning was repeated as described above using 50 µL of the phage solution from the first or
previous round of panning.
4.9. ELISA Test of the Candidate Phage Clones
The colonies obtained in percent of phage recovery experiment were used for ELISA. Single colonies
were streaked on 2× YTGT carbenicillin (100 µg/mL) agar plates and also grown in 300 µL of 2× YTGT
carbenicillin (100 µg/mL) broth in microfuge tubes. The plates were incubated at 37 ◦C overnight and
the cells were used for PCR and phagemid isolation later. An individual candidate phage clone from
a single colony used for phage preparation was named Phage Clone 1, or PC1 when TG1 contained
the recombinant phagemid; the same clone was named PC2 when phage adding helper phage to the
culture; finally, it was named PC3 when phage was resuspended. An aliquot of PC1 cultures was
stored in −80 ◦C as the primary culture. In addition, individual candidate phage clones were also
assigned unique identity. This combined designation was useful for organization of the experiment.
The microfuge tubes (labeled PC1 and the clone ID) were incubated at 37 ◦C overnight. From these
cultures, 50 µL were transferred to a new microfuge tube labeled PC2 and the clone ID containing
300 µL of 2× YTGT broth with 100 µg/mL carbenicillin and 5 × 108 Hyperphage. Incubation was
carried out at 37 ◦C for 1 h. The remaining culture was stored in 10% glycerol at −80 ◦C. The cells in the
culture were collected by centrifugation at 2000× g for 3 min at 4 ◦C. The supernatant was discarded,
and the cells were resuspended in 350 µL of 2× YTGT with carbenicillin, kanamycin added to a final
concentration of 100 µg/mL, and IPTG to 250 µM, followed by incubation at 30 ◦C overnight with
shaking. The microfuge tubes were centrifuged at 14,000 rpm for 10 min at 4 ◦C and 300 µL of the
supernatant containing the phage were transferred to a new microfuge tube labeled PC3 and the clone
ID. To this, 300 µL of blocking buffer (for phage precipitation) were added and incubated on ice for
10 min. Then 120 µL of 20% PEG were added to each tube and incubation was continued on ice for 1 h.
The microfuge tube was centrifuged at 14,000 rpm for 20 min at 4 ◦C. The supernatant was discarded,
and the phage PFUs were resuspended in 100 µL of ice-cold PBS. From the phage solution 50 µL were
mixed with equal volume of blocking buffer and applied to biotinylated lysozyme coated well for
ELISA as described above.
4.10. PCR, Enzyme Digestion and Sequence Analysis of the Phagemid Clones
The PC1 clones streaked on plates were used for screening by PCR and enzyme digestion and
isolation of phagemids for sequencing. PCR was performed in a 10 µL reaction volume using a
forward primer, CAPBSF1 (5′-ATGTGAGTTAGCTCACTCATTAGGC-3′), located upstream, and a
reverse primer, GPIIICTR2 (5′-TGTCGTCTTTCCAGACGTTAGTAAATG-3′), located downstream of
BglI cloning sites in the vector. The phagemid with any insert produced a fragment of 329 bp. The PCR
product was checked by agarose gel electrophoresis. In the case of screening for the VLRB.HEL
clones, the PCR product was digested with BglI and EcoRI to produce a small fragment (684 bp for
VLRB.HEL.21) which allowed screening for VLRB.HEL.21 clones. The candidates were sequenced
from DNA Sequencing Service of Operon, Fischer Scientific. Sequence contig assembly was done by
Vector NTI program (Invitrogen) and alignment was done by ClustalW and ClustalX version 2 [27].
4.11. Isolation of Bacterially Expressed VLRB Recombinant Proteins, Western Blotting, and
Immunohistochemistry (IHC)
VLRB.HEL21 was cloned in pET28+ vector for expression of His-tagged protein in E. coli BL21.
BL21 containing the recombinant plasmid was grown in 2× YT medium with 10 µg/mL of kanamycin
in a shaker at 250 rpm at 37 ◦C. When the OD reached 0.6, IPTG was added at a concentration of
1 mM/L and incubation was continued overnight at 30 ◦C. The cells were harvested by centrifugation
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at 4 ◦C, washed twice with ice-cold PBS, and finally resuspended in His-tag lysis buffer, 40 mL/L of
culture. It was incubated on ice for 30 min. Lysozyme was added at a concentration of 50 µg/mL and
RNaseA at 10 µg/mL and incubation was continued for another 30 min. The cell lysate was sonicated
on ice for 10 cycles, each with a 10 s pulse at 70% output and 30 s intervals. It was incubated on ice
for 10 min and then homogenized thoroughly, and again incubated on ice for 10 min. The process
was repeated twice more. For a freeze thaw cycle, the lysate was dipped into liquid nitrogen until
the entire content solidified and then incubated in 37 ◦C for 30 min. Then, the lysate was left at room
temperature and homogenized every 10 min. The lysate was centrifuged at 9000 rpm at 4 ◦C for 30 min.
The supernatant was transferred in a new tube and again centrifuged for 1 h. The supernatant was
transferred to a new tube and 2 mL of His-tag lysate buffer equilibrated Ni-NTA agarose beads was
added and incubated at 4 ◦C for 2 h. The lysate was poured into a high flow column. The column was
washed with 50 mL of wash buffer and eluted with 1.0 mL aliquots of elution buffer. Concentration of
the eluted protein was measured by BCA method.
The eluted fractions were electrophoresed in 10% SDS-PAGE (Lonza, Hayward, CA, USA), stained
with Coomassie brilliant blue solution (G-Biosciences, St. Louis, MO, USA), and destained with an
aqueous solution of 40% methanol and 10% glacial acetic acid. The eluted fractions having higher
concentration were pooled; however, the recombinant protein had many other bands associated with
it after His-tag purification. For Western blotting, SDS-PAGE was run, transferred (semi-dry) to a
nitrocellulose membrane using iBlot (Invitrogen) system. The blot was blocked with 5% blotto in
TBST (150 mM NaCl, 10 mM Tris, 0.1% Tween 20) for an hour at room temperature. It was incubated
with primary antibody, 4C4, at 1 µg/mL of blocking buffer overnight at 4 ◦C. The blot was washed
thoroughly with TBST and incubated with horseradish peroxidase (HRP) conjugated rabbit anti-mouse
IgG secondary antibody at 1:1000 dilution (Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA) for 2 h at room temperature. The blot was washed and a substrate solution (Luminata
Forte, Millipore, Temecula, CA, USA) was added. Image was obtained immediately using ChemiDoc
Imaging System (Bio-Rad, Hercules, CA, USA).
VLRB.IgM3P_4 was cloned in pADL23c phagemid for expression in E. coli BL21. A single colony
was isolated from E. coli containing the phagemid and was grown in 10 mL of LB liquid medium with
100 µg/mL of carbenicillin in a shaker at 250 rpm at 37 ◦C. After overnight incubation, the culture
was diluted in 1 L of LB medium supplemented with 2% glucose, and 100 µg/mL of carbenicillin was
added; incubation was continued, and optical density was measured at 600 nm every hour. At OD
0.6, cells were collected by centrifugation and resuspended in M9 liquid medium supplemented
with 2 mM MgSO4, 0.1 mM CaCl2, 0.4% glucose, and 1 mM thiamine-HCl. Carbenicillin was added
at a concentration of 50 µg/mL and the culture was incubated at 16 ◦C with shaking for an hour
for cells to acclimatize. Then, IPTG was added at a concentration of 500 nm/L and incubation was
continued overnight. Cell lysate preparation, isolation of His-tagged protein, and Western blotting
were performed as described above. As in VLRB.HEL21, the eluted fractions had many other bands
associated with it after His-tag purification of VLRB.IgM3P_4. Similar result was obtained when
VLRB.IgM3P_4 was cloned into pET28+ vector and expressed. The protein was dialyzed with 10 kD
cutoff spin column to remove salts. Then, the protein was again purified using the Ni-NTA bead and
was used for IHC.
IHC was performed using standard protocol [8]. Human tonsil sections were placed on a slide
and deparaffinized by three changes in xylene, 10 min each. The sections were rehydrated in serial
dilution of 100%, 95%, and 80% ethanol and finally in water. Heat-induced epitope retrieval (HIER) was
done in Na-citrate buffer (10 mM sodium citrate, pH 6.0) in a steamer for 15 min and cooled to room
temperature for 10 min. The slides were washed and immersed in PBST (PBS with 0.1% Triton × 100).
To block endogenous peroxidase, the slides were incubated with 3% aqueous solution of hydrogen
peroxide at room temperature and then washed with PBST again. The slides were perfused in PBST
with BSA (1%) blocking buffer for an hour at room temperature and then incubated with 5 µg of the
polled His-tag purified recombinant protein, VLRB.IgM3P_4 in 100 µL of blocking buffer (PBST with
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BSA) at 4 ◦C overnight. The slides were washed with PBST buffer and then incubated with anti-cMyc
antibody at 1:100 dilution (tag in the C-terminal of recombinant pADL23c phagemid, from Thermo
Fisher Scientific), under the same condition. The slides were washed with PBST and incubated with
HRP conjugated mouse secondary antibody at 1:500 dilution (Jackson ImmunoResearch Laboratories,
Inc.). Antigen–antibody complexes were visualized by DAB peroxidase substrate and counterstained
with Meyers hematoxylin (Vector Laboratories, Burlingame, CA, USA). VLRB.IgM3P_4 was also
detected with 4C4 at 1 µg/100 µL of blocking buffer. For the positive control, mouse anti-human IgM
antibody at 1:100 dilution (Biolegend, San Diego, CA, USA) was used.
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